A comparison of reboxetine and amitryptilline in the treatment of fibromyalgia syndrome with co-morbid depressive symptoms: an open-label preliminary study = Komorbid depresif semptomları olan fibromiyalji hastalarında reboksetin ve amitriptilin tedavilerinin karşılaştırılması: Açık ön çalışma

Konuk, N., Ortancil, O., Bostanci, B., Kiran, S. and Sapmaz, P. (2010) A comparison of reboxetine and amitryptilline in the treatment of fibromyalgia syndrome with co-morbid depressive symptoms: an open-label preliminary study = Komorbid depresif semptomları olan fibromiyalji hastalarında reboksetin ve amitriptilin tedavilerinin karşılaştırılması: Açık ön çalışma. Klinik Psikofarmakoloji Bulteni, 20(1), pp. 29-37. (doi: 10.1080/10177833.2010.11790631)

Full text not currently available from Enlighten.

Abstract

Objective: Fibromyalgia (FM) is a chronic debilitating disorder that results in millions of dollars of heathcare costs and lost wages each year worldwide. It is a significant public health concern and new treatments are needed. In this study, we aimed to compare the effectiveness of a widely used tricyclic antidepressant for FM (amitryptylline) and one that has not yet been widely used (reboxetine) for FM in a within-subject pre-posttreatment design. Additionally, since noradrenaline (NA) is thought to play a relevant role in the antinociceptive mechanisms, we also aimed to examine the effectiveness of reboxetine as a selective NA reuptake inhibitor (NARI) in patients with fibromialgia. Methods: Twenty-one patients with fibromyalgia were randomized to receive amitiriptylline (25–75 mg/day) or reboxetine (8 mg/day). Patients were administered the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depression and Anxiety Inventories (BDI, BAI), and the Hamilton Rating Scales for Depression and Anxiety (HAM-D, HAM-A) at the treatment weeks 2, 4, and 8. The intensity of the pain was recorded using a Visual Analog Scale (VAS). Results: We found both medications to be associated with improvement in pain (decreased VAS scores), FIQ scores, and depressive symptomotology. General linear model repeated measures analysis on the VAS and FIQ scores showed a significant decrease over time in both treatment groups without significant group difference or time x group interaction effect. There were no serious adverse events in both groups. Conclusions: This open trial demonstrated that either reboxetine or amitryptylline would be effective for the treatment of pain symptoms in patients with FM. Since open-label clinical effectiveness studies do not provide definitive conclusions about causality or efficacy, double blind, placebo-controlled studies in larger clinical groups are needed to reach a definitive conclusion. Our findings provide clinical researchers important information about the novel treatment options for FM.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Kiran, Professor Sibel
Authors: Konuk, N., Ortancil, O., Bostanci, B., Kiran, S., and Sapmaz, P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Public Health
Journal Name:Klinik Psikofarmakoloji Bulteni
Publisher:Cukurova Univ Tip Fakultesi Psikiyatri Anabilim Dali
ISSN:1017-7833

University Staff: Request a correction | Enlighten Editors: Update this record